Method and Apparatus for Determining Medication Dose Information Turning Glucose Sensor Data Into Insulin Dose Guidance

This patent describes methods, devices, and kits that work out a recommended insulin dose for a person with diabetes based on readings from a glucose sensor worn on the body. It comes from Abbott Diabetes Care Inc., the division of Abbott behind the FreeStyle Libre glucose monitoring system.

The Problem

People who manage diabetes with insulin have to make frequent, high-stakes decisions about how much to inject. Too little insulin leaves blood sugar dangerously high; too much can cause a hypoglycaemic crash. Traditionally the calculation depends on a finger-prick reading, a mental estimate of the carbohydrates in a meal, and a set of personal correction factors that a clinician has tuned. That is a lot to juggle several times a day, and mistakes are easy to make. Modern sensors now stream glucose data continuously, but a raw number on a screen still leaves the user to translate it into an actual dose. The challenge is to close that gap and turn live sensor data directly into clear, safe dose guidance.

What This Invention Does

The invention links an analyte sensor to a dose calculation so the system can recommend how much insulin to administer. Glucose data determined by the sensor is fed into a processor that applies the user’s dose settings, such as insulin sensitivity and target range, and produces a recommended dose. Because the recommendation is built on live analyte readings rather than a single stale finger-prick, it can take account of where glucose is now and, in richer versions, which way it is trending. The patent covers the methods for making this determination, the devices that carry it out, and the kits that package the sensor and dose-calculation function together, giving a rounded claim over the whole workflow from sensor reading to dose suggestion.

Key Features

• Sensor-driven dosing. A recommended insulin dose is calculated from glucose data determined by an analyte sensor worn by the user.
• Personalised settings. The calculation applies the user’s own parameters, so the guidance reflects individual insulin needs rather than a generic rule.
• Complete workflow. The claims cover methods, devices, and kits, spanning the path from sensor measurement to dose recommendation.
• Built for continuous data. The approach suits sensors that report glucose frequently, allowing dose guidance to stay current.
• Aimed at safer decisions. By turning raw readings into a concrete dose, the system reduces the mental arithmetic and estimation errors of manual dosing.

Who Is Behind It

The applicant is Abbott Diabetes Care Inc., part of the global healthcare company Abbott, and the maker of the widely used FreeStyle Libre glucose sensors. The named inventors include Marc Barry Taub, Jai Karan, Erwin Satrya Budiman, and Timothy Christian Dunn. This filing is a divisional application from an earlier related Australian application.

Why It Matters

Diabetes affects hundreds of millions of people worldwide, and insulin dosing errors are a leading cause of avoidable hospital visits. Tools that connect a glucose sensor directly to a dose recommendation move users away from guesswork and toward data-driven decisions, which is the direction the whole field of continuous glucose monitoring has been heading. Protecting this method in Australia supports the rollout of connected diabetes management systems in a market with high rates of the condition.

Related Concepts

• Continuous glucose monitoring – the sensing technology that feeds this system its data.
• Insulin – the medication whose dose the invention helps determine.
• Diabetes – the condition this dosing guidance is designed to manage.
• Blood sugar – the measured quantity that drives the dose calculation.
• Artificial pancreas – the broader class of systems that automate insulin decisions.

---

AU 2026202005 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.